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Human genetic variation contributes to differences in susceptibility to HIV-1 infection. To search for novel
host resistance factors, we performed a genome-wide association study (GWAS) in hemophilia patients
highly exposed to potentially contaminated factor VIII infusions. Individuals with hemophilia A and a docu-
mented history of factor VIII infusions before the introduction of viral inactivation procedures (1979–1984)
were recruited from 36 hemophilia treatment centers (HTCs), and their genome-wide genetic variants were
compared with those from matched HIV-infected individuals. Homozygous carriers of known CCR5 resist-
ance mutations were excluded. Single nucleotide polymorphisms (SNPs) and inferred copy number variants
(CNVs) were tested using logistic regression. In addition, we performed a pathway enrichment analysis, a
heritability analysis, and a search for epistatic interactions with CCR5 D32 heterozygosity.
A total of 560 HIV-uninfected cases were recruited: 36 (6.4%) were homozygous for CCR5 D32 or m303.
After quality control and SNP imputation, we tested 1 081 435 SNPs and 3686 CNVs for association with
HIV-1 serostatus in 431 cases and 765 HIV-infected controls. No SNP or CNV reached genome-wide signifi-
cance. The additional analyses did not reveal any strong genetic effect.
Highly exposed, yet uninfected hemophiliacs form an ideal study group to investigate host resistance fac-
tors. Using a genome-wide approach, we did not detect any significant associations between SNPs and HIV-1
susceptibility, indicating that common genetic variants of major effect are unlikely to explain the observed
resistance phenotype in this population.
INTRODUCTION
A single exposure to a transfusion with HIV-contaminated
blood or clotting factor concentrates carries a risk of infection
of 90%, far greater than that of any other risk exposure (1).
This is clearly illustrated by the disastrous consequences of
widespread use of contaminated plasma-derived clotting
factor concentrates for the treatment of hemophilia in the
early days of the current AIDS pandemic.
Hemophilia A is an inherited X-linked bleeding disorder
affecting 1 in 5000–1 in 10 000 males. It is caused by muta-
tions in the factor 8 gene (F8) on the X chromosome,
leading to reduced levels of factor VIII (FVIII) activity in
the circulation. Replacement of FVIII is necessary to prevent
morbidity and mortality associated with uncontrolled bleed-
ing. The use of donor FVIII concentrates derived from
pooled plasma from up to 100 000 donors was the mainstay
of hemophilia treatment until recombinant factor products
were introduced in the 1990s (2,3). Prior to 1984, factor con-
centrates were not subjected to viral inactivation processes and
as a result, a large proportion of patients with hemophilia A
became infected with HIV-1 (4–8). The risk of infection
was correlated with the severity of the disease: individuals
with severe hemophilia experienced more bleeding episodes
requiring treatment with FVIII concentrates or were treated
prophylactically two or three times per week, and the quantity
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of concentrates correlated directly with the probability of ac-
quiring HIV-1 infection (9). However, infection was not uni-
versal, even among patients with severe hemophilia.
Individuals, who were likely exposed, yet remain HIV unin-
fected are here referred to as exposed uninfected (EU).
It is already known that human genetic variation contributes
to differences in susceptibility to HIV-1 infection. Homozy-
gosity for a 32 bp deletion in the gene coding for the HIV-1
co-receptor CCR5 results in the absence of CCR5 expression
at the cell surface, offering protection against R5 strains of
HIV-1, the usual infecting virus (10–12). The CCR5 D32/
D32 homozygous genotype is found in 1% of healthy indi-
viduals of European descent, but is rare in non-European
populations (13). A rarer mutation in CCR5, m303, also abro-
gates expression and confers resistance in homozygotes or
compound heterozygotes with CCR5 D32 (14). No other
host genetic polymorphism has been consistently shown to
protect against HIV-1 acquisition (15). Of note, several
studies in Europe and North America have shown that the fre-
quency of CCR5 D32/D32 is significantly higher in
HIV-uninfected hemophiliacs than in the general population
(up to 15% compared with ≤1%), with the highest frequencies
in those with severe hemophilia (16–20). In contrast, CCR5
D32/D32 is rare or absent in hemophiliacs who acquired
HIV infection (20).
We here present a genome-wide association study (GWAS)
that aims at discovering additional genetic polymorphisms
associated with reduced susceptibility to HIV-1. A clearer
understanding of host genetic resistance against HIV-1 infec-
tion is of enormous importance to identifying novel prophylac-
tic drug targets as well as correlates of protection for rational
HIV-1 vaccine design.
RESULTS
Study participants and genotypes
A total of 483 individuals with hemophilia A were included in
the CHAVI014 protocol from 36 hemophilia treatment centers
(HTCs) in nine countries (Table 1). Samples from an addition-
al group of 77 highly exposed hemophiliacs were obtained
from the Multicenter Hemophilia Cohort Study (MHCS)
(6,19). All study participants received potentially contami-
nated FVIII concentrates between 1979 and 1984 and had at
least one documented negative HIV-1 screening test at a
later date. Most patients had severe hemophilia and were posi-
tive for chronic or resolved hepatitis C virus (HCV) infection,
a marker of blood-borne pathogen exposure (Table 1). The
control population comprised of 823 HIV positive, ethnically
matched individuals from the Multicenter AIDS Cohort
Study (MACS).
To reduce heterogeneity, we excluded the only three female
subjects who were recruited in CHAVI014. Targeted genotyp-
ing of the CCR5 protective variants identified 35 hemophilia
cases as homozygous for the D32 deletion and one case as
homozygous for the m303 variant. There were no D32/m303
compound heterozygotes. We observed a consistent enrich-
ment for CCR5 D32 homozygosity across study sites and
countries, closely reflecting the known north–south decreas-
ing cline of D32 allele frequency in European populations:
9.4% of individuals of northern European ancestry, 2.6% of
central Europeans and 0.9% of southern Europeans were
found to be homozygous, versus 2, 0.5 and 0.1% in the re-
spective general populations (13,21). Because the HIV EU
phenotype of the 36 subjects carrying CCR5 homozygous
mutations was already explained genetically, they were not
included in the GWAS. The frequency of D32 heterozygosity
was not increased in the EU cohort (n ¼ 92/560, 16.4%) in
comparison to control populations, implying the absence of
additional CCR5 variants that could form protective com-
pound heterozygotes with the D32 deletion.
A total of 521 of the initial sample of 560 EU cases and 823
HIV positive controls were genotyped: 16 samples did not
pass initial quality control filtering. An additional 43 indivi-
duals were removed due to cryptic relatedness: this high
number of related individuals in our study population is unsur-
prising considering the familial clustering of hemophilia.
Finally, we excluded 90 population outliers that were identified
through principal component analysis of the genotyping data.
The final study population consisted in 430 EU hemophilia
cases and 765 HIV positive controls. After all quality control
steps, 890 599 single-nucleotide polymorphisms (SNPs) were
used for imputation based on the HapMap 3 CEU reference
set, resulting in a total of 1 081 435 SNPs used for association
testing. The coordinates of nine significant principal component
axes were included as covariates in all regression models.
Using PennCNV, we identified 2543 deletions and 1143 dupli-
cations in 3375 variable genomic regions: the number of copy
number variants (CNVs) was consistent with data from the
1000 Genomes Project (22).
Power calculation
With our final numbers of cases and controls, the study had
80% power to detect associated variants with a genotype
relative risk (GRR) of two or more. Table 2 shows the GRR
required for a polymorphism to be significantly associated
with resistance against HIV infection at the genome-wide
level (Pthreshold ¼ 5E208), under different genetic models
and with various minor allele frequencies (MAFs).
Genome-wide association analyses
After imputation, we tested all SNPs for association with HIV
resistance under additive, dominant and recessive models
using logistic regression. No SNP reached genome-wide
significance (Fig. 1A) under any of the genetic models. The
distribution of observed P-values was very similar to the
null expectation, as shown in Figure 1B: a l value of 1.01
indicated that the association statistics were not confounded
by population stratification. As a comparison, the CCR5 D32
variant strongly associated with HIV resistance under a reces-
sive genetic model (P ¼ 9.4E215) in the initial study popula-
tion consisting of 560 cases and 823 controls.
Since the only known genetic variant associated with HIV
resistance (CCR5 D32) also impacts HIV disease progression
(10), we sought to increase power for detecting genetic
effects by meta-analyzing the current association results with
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those from a GWAS on HIV control (23). We observed no
genome-wide significant associations after meta-analysis
of results under additive models or when combining additive
results from the HIV control GWAS with recessive model
results from the present study (i.e. imitating the known
effects of CCR5 D32).
We further addressed whether combining SNP effects or
testing for epistatic interactions between genome-wide SNPs
and CCR5 D32 heterozygosity could improve sensitivity for
detecting genetic influences on HIV resistance. To achieve
this, we performed pathway enrichment, a heritability analysis
assessing additive genetic effects and a genome-wide inter-
action analysis with CCR5 D32. In all cases, no significant evi-
dence for enrichment or interaction was observed further,
suggesting a lack of strong genetic effects of common variants
on HIV resistance.
DISCUSSION
Individuals with hemophilia, who were exposed to potentially
contaminated blood products, yet were not infected by HIV-1
in the early years of the pandemic, form an ideal study group
to investigate host resistance factors. Our study represents an
unprecedented effort to identify and prospectively recruit
such individuals. Through an international collaboration in-
volving 36 HTCs in nine countries and three continents, we
obtained informed consent, clinical information and genetic
material from 483 subjects. Those were combined with an
additional set of EU individuals from the MHCS, resulting
in a total number of 560 cases, which were compared with a
higher number of ethnically matched controls at more than
one million polymorphic sites across the genome.
The possibility of identifying associated variants depends
on an actual enrichment of resistance alleles—or depletion
of susceptibility alleles—in the case population. The incorrect
inclusion of non-exposed individuals (misclassification bias)
would decrease study power, because they would most
likely be susceptible. Therefore, we applied strict selection cri-
teria to ensure that our EU subjects had a very high likelihood
of effective exposure to HIV-1. All included cases had a docu-
mented history of treatment with FVIII concentrates with a
high likelihood of HIV-1 contamination. Due to the severity
of hemophilia, they received a relatively high number of
FVIII infusions (median 51), each derived from pooled
plasma from thousands of donors. Most subjects were infected
by HCV, confirming actual exposure to blood-borne patho-
gens. The majority of patients treated in the same HTCs
were infected before 1984 (4–8). Finally, the observed enrich-
ment of CCR5 D32 homozygosity in cases (6.4% versus ≤1%
in European populations) is a clear indicator of effective
HIV-1 exposure.
The choice of an adequate control population represented an
essential step in the study design. We chose to compare EU
cases with HIV-1-infected patients, to make certain that all
controls were in fact susceptible. Alternative options would
have been to select either unexposed hemophilia subjects or
population-level samples as controls. We considered, however,
that there was no advantage in matching cases and controls
for a monogenic disease that is genetically unrelated to HIV-1
susceptibility, and that using either alternative group could
reduce power because potentially resistant subjects would not
be excluded. An additional concern was that hemophilia cases
were selected on the basis of their resistance to intravenously
administered blood products, whereas controls would largely
consist of individuals infected through mucosal exposure. This
is unlikely to lead to substantial bias, as mechanisms involved
in susceptibility or resistance in the intravenous compartment
should also impact the likelihood of HIV-1 acquisition after
mucosal exposure, as observed for CCR5-associated resistance.
Our genome-wide analysis did not reveal any statistically
significant association between SNPs or CNVs and resistance
against HIV-1 infection. Furthermore, we did not find any evi-
dence for genetic effects in a pathway enrichment analysis, a
heritability analysis, and a search for epistatic interactions
with CCR5 D32 heterozygosity. Our results strongly suggest
that common genetic variants with a major effect do not
play a major role in determining susceptibility to HIV-1 in
our study population. During the past two decades, several
cohorts of EU individuals, identified by different modes of
HIV-1 exposure, have been studied for genetic factors that
might account for their apparent resistance to infection (24),
but only CCR5 variation has been consistently shown to
confer any degree of protection. Additional gene variants
Table 1. Characteristics of EU hemophilia cases
Male gender (n, %) 557 (99.5)
Caucasian ethnicity (n, %) 516 (92.1)
Birth year (median, IQR) 1967 (1954–1976)
Country (n, %)
USA 203 (36.3)
UK 110 (19.6)
Switzerland 61 (10.9)
Italy 60 (10.7)
Netherlands 40 (7.1)
Spain 36 (6.4)
Greece 20 (3.6)
Germany 19 (3.4)
Japan 11 (2)
Severity of hemophilia (n, %)a
Severe (,1% normal FVIII activity) 406 (84.1)
Moderate (1% ,normal FVIII activity ,5%) 77 (15.9)
Number of FVIII infusions 1979–1984 (median, IQR)a 51 (7–296)
Hepatitis C status (n, %)a
Never infected 29 (6)
Spontaneous clearance 70 (14.5)
Chronically infected 262 (54.2)
Successfully treated 122 (25.3)
Protective CCR5 genotype: homozygosity D32 or m303 36 (6.4)
aInformation was only available for the 483 CHAVI014 participants.
Table 2. Minimal GRR required for 80% power for variant detection in the
genome-wide association analyses
Genetic model
MAF Additive Dominant Recessive
5% 2.9 3 36.5
20% 2 2.4 5.3
Power was calculated using the present sample size and a genome-wide
significance threshold of P , 5E208.
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were reported to protect against acquisition or to increase sus-
ceptibility to infection, but they are, at best, supported by weak
statistical evidence, and none has been convincingly replicated
(15). The negative result of our GWAS—one of the largest
genetic studies of HIV-1 acquisition to date, performed in the
most exposed population, in accordance with the latest standard
of genomic research—confirms the absence of common protect-
ive variants of large effect in individuals of Western European
ancestry, beyond CCR5: it also means that similarly sized
GWASs are unlikely to reveal any genetic association in
lower exposure cohorts (sexual transmission, intravenous drug
use, mother-to-child transmission).
The exclusive focus on whites is obviously an important
limitation of our study. A small number of Japanese indivi-
duals were recruited in the CHAVI014 protocol (n ¼ 11),
but could not be included in the association analysis due to
concerns about stratification and to a lack of ethnically
matched controls. To date, the only GWAS of HIV-1 acquisi-
tion performed in non-whites did not identify any association
in a population from Malawi (25). Additional, large-scale
studies of individuals from various ethnic backgrounds are a
clear priority in the field.
Our GWAS was designed to identify genetic variants with
relatively high MAFs (.5%) and moderate to high GRR
(≥2). Consequently, two categories of genetic variants could
still be involved in the HIV-1 resistance phenotype observed
in epidemiological studies: common variants with weak
effects and rare variants (26,27). Several efforts are underway
to explore these non-exclusive possibilities. The HIV host gen-
etics community is notably joining forces to run a large
meta-analysis of existing genome-wide studies (28). Also,
thanks to affordable sequencing technology, it is now feasible
to perform exhaustive searches for rare causal variants
throughout the exome or the genome of EU individuals. The
combination of these approaches in various populations will
finally delineate the impact of human genetic diversity on
HIV-1 susceptibility.
MATERIALS AND METHODS
Study participants
The CHAVI014 study was set up to obtain peripheral blood
specimens from HIV-1 exposed, yet uninfected subjects with
hemophilia A to study the genetic factors that may influence
susceptibility and resistance to HIV-1 infection. Potentially
eligible patients were identified from a search of hemophilia
registries, surveillance programme databases or other HTC
databases. Individuals 18 years of age or older with moderate
or severe hemophilia A (,5 IU/dl or ,1 IU/dl normal FVIII
activity, respectively) were eligible if they had documented
treatment with a plasma-derived FVIII concentrate between
1 January 1979 and 31 December 1984 and documented HIV-
negative test. The number of treatment episodes during the
high-risk exposure period was recorded. In a separate recruit-
ment effort, retrospective samples from a well-characterized
cohort of highly exposed, yet uninfected hemophiliacs were
obtained through collaboration with J.J.G. and the MHCS
(6,19).
HIV-infected individuals from the MACS that had been
genotyped in the context of a previous GWAS (23) were used
as controls: none of them were hemophiliacs, and the predomin-
ant mode of HIV acquisition was homosexual contact. Briefly,
the MACS was established in 1983 and includes 6972 adult
homosexual and bisexual men from four metropolitan areas, Bal-
timore, Chicago, Los Angeles and Pittsburgh, recruited during
three recruitment periods, 1984–1985, 1987–1991 and 2001–
2003.
Local institutional review boards at each participating center
approved the study, and all participants provided informed
consent for genetic testing.
Genotypes
Genomic DNA was extracted from 10 ml of whole blood.
CCR5 D32 and m303 genotypes were assessed by in-house
taqman assays: individuals with known CCR5 protective gen-
otypes (homozygosity for any of the variant or compound het-
erozygosity) were excluded from the subsequent GWAS.
Genome-wide genotyping was done on Illumina Human 1M
or 1Mduo SNP chip, containing 1 072 820 and 1 271 154
SNPs, respectively.
We carried out a series of SNP and sample quality control
procedures: polymorphisms were filtered based on missing-
ness (dropped if called in ,99% of participants), MAF
(dropped if the value was ,1%) and severe deviation from
Hardy–Weinberg equilibrium (dropped if P , 5E208).
Figure 1. Logistic regression results. (A) Manhattan plot of association results from the additive model shows no significant association signal throughout the
genome (the dotted red line indicates the significance threshold of 5E208). (B) QQ plot demonstrates that the observed distribution of P-values corresponds to
the expected distribution under the null hypothesis for all models (additive in black, dominant in blue, recessive in green), indicating that potential confounders
are well controlled.
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Samples were filtered based on genotyping quality (dropped if
call rate ,95%) and a gender check (heterozygosity testing).
SNPs were then used to identify cryptic relatedness between
study participants: we estimated the sharing of genetic infor-
mation by estimating identity by descent (IBD), and excluded
one randomly selected individual in each pair of DNA samples
showing .12.5% of estimated IBD, corresponding to first-
degree cousins. To control for the possibility of spurious asso-
ciations resulting from population stratification, we used a
modified Eigenstrat method, which derives the principal com-
ponents of the correlations among gene variants (29): popula-
tion outliers were discarded, and the coordinates of the
significant principal component axes were included in the as-
sociation tests to correct for residual stratification.
To increase the coverage of genomic variation, we imputed
the genotyping data using MACH software with HapMap 3
CEU as a reference set (30); SNPs with r2 ,0.3 and/or an
MAF ,1% were removed.
CNVs were derived from non-imputed SNPs using
PennCNV software (31), separately for the 1M and the
1Mduo chips. To avoid spurious CNV calls, deletions or dupli-
cations overlapping centromeric, telomeric and immunoglobu-
lin regions were discarded. Finally, only CNVs present in at
least two samples were considered for association analysis.
Association analyses
Logistic regression was used to assess the differences in geno-
type frequencies of SNPs and CNVs between EU individuals
and HIV-infected controls under additive, recessive and dom-
inant genetic models, and for interaction analysis between
genome-wide SNPs and CCR5 D32 heterozygosity. To
control for population structure, the coordinates of five signifi-
cant Eigenstrat axes were included as covariates in all models.
We used the CaTS Power Calculator for Genome-Wide Asso-
ciation Studies software (http://www.sph.umich.edu/csg/abeca
sis/CaTS/) for power calculations, PLINK (http://pngu.mgh.ha
rvard.edu/~purcell/plink/) for logistic regression analyses and
WGAViewer (http://compute1.lsrc.duke.edu/softwares/
WGAViewer/) for evaluation and annotation of the association
statistics. Bonferroni’s correction was applied for multiple
testing.
Meta-analysis of association results from an HIV control
GWAS
The CCR5 D32 deletion provides proof of concept that genetic
variants can impact both HIV acquisition and disease progres-
sion. Thus, we sought to improve power for variant detection
by combining association results from the HIV resistance ana-
lysis with those from a GWAS on HIV control. The HIV
control dataset includes 815 members of the Swiss HIV
Cohort Study typed on the Illumina HumanHap 550 BeadChip
and imputed using the HapMap 3 European sample as refer-
ence as previously described (23,32). We meta-analyzed the
results from additive genetic models in both studies by com-
bining z-scores that incorporated effect direction in both
studies (assuming variants that decrease HIV susceptibility
also decrease set point viral load) (33). For combining additive
association results from the GWAS on HIV control with
recessive model results from the recent study (i.e. directly
mimicking the observed CCR5 D32 effect), we used Fisher’s
method for combining P-values.
Assessment of enrichment of SNPs association signal in
biological pathways
We used MAGENTA (34) to search for abundance of SNPs
association signal across pathways using the default para-
meters to define gene boundaries (mapping to hg18) and to
correct for the confounding effects of gene size and linkage
disequilibrium between SNPs. Approximately 10 000 gene
sets defined by publicly available resources were used.
We further added custom gene sets relevant to HIV biology
defined by: whole genome siRNA knockdown screens (35),
human–HIV protein interactions (36) and a curated list of
interferon-stimulated genes (37). We used the false discovery
rate P-value correction within MAGENTA to assess
significance.
Heritability analysis
To investigate a role for measurable, additive genetic contribu-
tions to the HIV resistance phenotype, we used GCTA (38).
We performed strict sample and SNP quality control as
described in (39) and estimated the total genetic variance
explained by genome-wide SNPs and the narrow-sense herit-
ability assuming a trait prevalence of 1%. Genetic variance
was estimated using the underlying liability scale with the
narrow-sense heritability calculated as the proportion of total
phenotypic variance that is due to additive genetic effects.
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